Norgestrel And Ethinyl Estradiol has 40 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. Notable interactions include combinations with Dasabuvir, Ombitasvir/Paritaprevir/Ritonavir, Amprenavir. Patients taking Norgestrel And Ethinyl Estradiol should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 40
- Contraindicated
- 2
- Moderate
- 30
- Minor
- 2
Contraindicated (2)
- Norgestrel And Ethinyl Estradiol + Dasabuvir— Do not co-administer with ombitasvir/paritaprevir/ritonavir combination due to potential for ALT elevations.
- Norgestrel And Ethinyl Estradiol + Ombitasvir/Paritaprevir/Ritonavir— Do not co-administer due to potential for ALT elevations and liver enzyme elevation risk.
Moderate (30)
- Norgestrel And Ethinyl Estradiol + Amprenavir— HIV protease inhibitor may significantly decrease plasma concentrations of estrogen and/or progestin.
- Norgestrel And Ethinyl Estradiol + Aprepitant— May decrease plasma concentrations and efficacy of contraceptive; may increase breakthrough bleeding.
- Norgestrel And Ethinyl Estradiol + Atazanavir— HIV protease inhibitor may significantly increase plasma concentrations of estrogen and/or progestin.
- Norgestrel And Ethinyl Estradiol + Atorvastatin— Increases AUC of ethinyl estradiol by approximately 20-25%.
- Norgestrel And Ethinyl Estradiol + Barbiturates— May decrease plasma concentrations and efficacy of contraceptive; may increase breakthrough bleeding.
- Norgestrel And Ethinyl Estradiol + Bosentan— May decrease plasma concentrations and efficacy of contraceptive; may increase breakthrough bleeding.
- Norgestrel And Ethinyl Estradiol + Carbamazepine— May decrease plasma concentrations and efficacy of contraceptive; may increase breakthrough bleeding.
- Norgestrel And Ethinyl Estradiol + Colesevelam— Significantly decreases AUC of ethinyl estradiol; effect reduced when given 4 hours apart.
- Norgestrel And Ethinyl Estradiol + Darunavir— HIV protease inhibitor may significantly decrease plasma concentrations of estrogen and/or progestin.
- Norgestrel And Ethinyl Estradiol + Etravirine— HCV protease inhibitor may significantly increase plasma concentrations of estrogen and/or progestin.
- Norgestrel And Ethinyl Estradiol + Felbamate— May decrease plasma concentrations and efficacy of contraceptive; may increase breakthrough bleeding.
- Norgestrel And Ethinyl Estradiol + Fluconazole— CYP3A4 inhibitor may increase plasma hormone concentrations.
- Norgestrel And Ethinyl Estradiol + Grapefruit Juice— CYP3A4 inhibitor may increase plasma hormone concentrations.
- Norgestrel And Ethinyl Estradiol + Griseofulvin— May decrease plasma concentrations and efficacy of contraceptive; may increase breakthrough bleeding.
- Norgestrel And Ethinyl Estradiol + Indinavir— HIV protease inhibitor may significantly increase plasma concentrations of estrogen and/or progestin.
- Norgestrel And Ethinyl Estradiol + Itraconazole— CYP3A4 inhibitor may increase plasma hormone concentrations.
- Norgestrel And Ethinyl Estradiol + Ketoconazole— CYP3A4 inhibitor may increase plasma hormone concentrations.
- Norgestrel And Ethinyl Estradiol + Lopinavir And Ritonavir— HIV protease inhibitor may significantly decrease plasma concentrations of estrogen and/or progestin.
- Norgestrel And Ethinyl Estradiol + Nelfinavir— HIV protease inhibitor may significantly decrease plasma concentrations of estrogen and/or progestin.
- Norgestrel And Ethinyl Estradiol + Nevirapine— HCV protease inhibitor may significantly decrease plasma concentrations of estrogen and/or progestin.
- Norgestrel And Ethinyl Estradiol + Oxcarbazepine— May decrease plasma concentrations and efficacy of contraceptive; may increase breakthrough bleeding.
- Norgestrel And Ethinyl Estradiol + Phenytoin— May decrease plasma concentrations and efficacy of contraceptive; may increase breakthrough bleeding.
- Norgestrel And Ethinyl Estradiol + Rifabutin— May decrease plasma concentrations and efficacy of contraceptive; may increase breakthrough bleeding.
- Norgestrel And Ethinyl Estradiol + Rifampin— May decrease plasma concentrations and efficacy of contraceptive; may increase breakthrough bleeding.
- Norgestrel And Ethinyl Estradiol + Ritonavir— HIV protease inhibitor may significantly decrease plasma concentrations of estrogen and/or progestin.
- Norgestrel And Ethinyl Estradiol + Rosuvastatin— Increases AUC of ethinyl estradiol by approximately 20-25%.
- Norgestrel And Ethinyl Estradiol + Rufinamide— May decrease plasma concentrations and efficacy of contraceptive; may increase breakthrough bleeding.
- Norgestrel And Ethinyl Estradiol + St. John'S Wort— Herbal product may decrease plasma concentrations and efficacy of contraceptive; may increase breakthrough bleeding.
- Norgestrel And Ethinyl Estradiol + Tipranavir— HIV protease inhibitor may significantly decrease plasma concentrations of estrogen and/or progestin.
- Norgestrel And Ethinyl Estradiol + Topiramate— May decrease plasma concentrations and efficacy of contraceptive; may increase breakthrough bleeding.
Minor (2)
- Norgestrel And Ethinyl Estradiol + Acetaminophen— May increase plasma ethinyl estradiol concentrations.
- Norgestrel And Ethinyl Estradiol + Ascorbic Acid— May increase plasma ethinyl estradiol concentrations.